B

BrainChild Bio

CAR T therapies targeting CNS tumors

Director Program Lead

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeSeattle, WA, USA$195k - $215k /yrHybrid

About the Job

Requirements

  • 10+ years of experience in the biotechnology or cell therapy industry.
  • 3+ years in cross-functional team leadership roles.
  • Experience in a key contributory or leadership role on cell therapy development teams.
  • Excellent communication skills and demonstrated aptitude and experience in influencing stakeholders.

Responsibilities

  • Lead the cross-functional program development team for a preclinical program through investigational new drug (IND)-enabling activities and into the clinic as an early-phase clinical-stage asset.
  • Lead development of program strategy and goals aligned with corporate goals, and collaborate with cross-functional areas to enable execution of program deliverables.
  • Ensure continued progress and development by proactively managing new and incoming risks, functional-area misalignments, or challenges, and recognize when to escalate issues to executive leadership for remediation or endorsement.
  • Manage the program budget in coordination with functional teams and Finance to ensure alignment with the forecast.
  • Collaborate with project management to develop and execute communication plans that deliver program updates to stakeholders and company leadership.
  • Foster a culture of accountability, collaboration, and operational excellence, ensuring alignment across internal teams and external partners to accelerate program execution.
  • Use experience to encourage a collaborative team approach and help drive the delivery of therapies for patients.

About the Company

BrainChild Bio

CAR T therapies targeting CNS tumors

What BrainChild Bio does: It develops CAR T cell therapies to treat tumors in the central nervous system, focusing on children first and then expanding to adults with glioblastoma. How its product works: The lead therapy, BCB-276, uses a patient’s own T cells engineered to target B7-H3, and is given directly into the cerebrospinal fluid to reach brain and spine tumors. The company is also advancing a triple-targeting candidate, BCB-214, toward initial glioblastoma testing. How it differs from competitors: BrainChild Bio relies on autologous CAR T cells delivered locoregionally into CSF, with technology licensed from Seattle Children’s and strong ties to that institution, aiming at pediatric DIPG and other CNS cancers. What its goal is: To complete the Phase 2 ILLUMINATE trial to support a future regulatory filing for BCB-276 and to broaden its pipeline for CNS tumors, including early work on glioblastoma, supported by a recent $116 million Series A.

Company size
51-200
Company stage
Series A
Total funding
$116M
Headquarters
Seattle, WA
Founded
Not listed

Recently Posted Jobs

Explore more opportunities at BrainChild Bio

See more jobs